Cancer Research Institute, NYC, 6/23 – 6/24/2016: Will combination of adoptive t-cell therapy and anti-checkpoint inhibitor therapies be the next wave?
Reporter: Aviva Lev-Ari, PhD, RN
Overview
The Conference Forum is delighted to present the inaugural Rational Combinations 360°, the only event addressing business aspects, novel clinical trial designs and scientific developments for combination immunotherapies.
With promising cancer immunotherapies in the clinic and an encouraging pipeline of new targets being developed, additional discoveries are now under way to determine the most effective rational combinations that are personalized for individual patients and for specific tumor types. Increased emphasis on prioritizing combinations will be crucial for decision-making. Both small and large companies are now racing to bring game-changing combination therapies to the market. As a result, novel therapies and innovative trial designs are creating increased momentum for investment/business development opportunities.
Designed by lead advisor Dr. Ian McCaffery (Corvus Pharmaceuticals) along with advisory board members Drs Axel Hoos (GSK), Michael Kalos (Eli Lilly), Patricia Marinello (Merck) and Omid Hamid (The Angeles Clinic and Research Institute), Rational Combinations 360°will provide the most up-to-date progress on combination developments from business aspects, clinical advancements and scientific data that will help prioritize the best cancer treatments for individual patients and tumor types.
AGENDA ANDA SPEAKERS
http://theconferenceforum.org/conferences/rational-combinations-360/overview/?utm_source=iContact&utm_medium=email&utm_campaign=Jessica&utm_content=Rational+Combos+-+EB
|
Dr. Patrick Hwu, MD Anderson Cancer Center Confirmed to Keynote |
|||||||||||||||||||||||||||||||||
|
We are delighted to confirm Dr Patrick Hwu who will deliver a keynote on the next innovation behind combination therapy, specifically focusing on: what’s next after checkpoint combinations including:
MD Anderson Cancer Center
|
|||||||||||||||||||||||||||||||||
SOURCE
From: Jessica Rothenberg <jessica@tcfllc.org>
Reply-To: <jessica@tcfllc.org>
Date: Monday, May 2, 2016 at 9:27 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Keynote Announcement: Patrick Hwu, MD Anderson Confirmed for Immuno-Oncology Conference
2012pharmaceutical
sjwilliamspa